Arcellx is a biotechnology company reimagining cell therapy through the development of immunotherapies. Co.'s D-Domain powered autologous and allogeneic Chimeric Antigen Receptor T cells (CAR-Ts) includes classical single infusion CAR-Ts (ddCARs) and dosable and controllable universal CAR-Ts (ARC-SparX), to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. Co.'s main ddCAR product candidate, CART-ddBCMA, is for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). Co. is developing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia and myelodysplastic syndrome. We show 3 historical shares outstanding datapoints in our coverage of ACLX's shares outstanding history.
Understanding the changing numbers of ACLX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACLX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACLX by allowing them to research ACLX shares outstanding history
as well as any other stock in our coverage universe. |
Free ACLX Email Alerts:
Video: Shares Outstanding Importance
